Drug Profile
Research programme: mucopolysaccharidoses therapeutics - Dorphan
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator DORPHAN S.A.
- Class
- Mechanism of Action Glycosaminoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Lysosomal storage diseases; Mucopolysaccharidosis III
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Lysosomal storage diseases in Switzerland
- 28 Aug 2020 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Switzerland
- 15 Jul 2016 Research programme: mucopolysaccharidoses therapeutics - Dorphan is available for licensing as of 15 Jul 2016. http://www.dorphan.com/